It was determined that NKG2A VHH possesses biological activity in mice, suggesting that an appropriate amount of NKG2A VHH could block the NKG2A receptor, inhibit the binding of the Qa-1b ligand to the NKG2A receptor directly, and thus activate the immune system to target and kill tumor cells. This evidence concerns the gene KLRC1 and neoplasm.